{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ITGR",
  "name": "Integer Holdings Corporation",
  "url": "https://frontierpicks.com/dossiers/ITGR/",
  "json_url": "https://frontierpicks.com/dossiers/ITGR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Signed-deal instrument since 2026-08-03: KKR's $127.00 all-cash agreement leaves $1.80 above the 2026-08-21 close of $125.20 (~1.4%), unchanged from two weeks earlier. The paperwork stage has begun with no paperwork — no merger proxy on file as of 2026-08-22, no HSR disclosure — against a year-end 2026 closing guide and a 2027-05-02 outside date.",
  "invalidation_trigger": "A daily close below $118 — more than a 7% discount to the $127 cash consideration — marks the market repricing completion odds; an 8-K disclosing an HSR second request, or a merger proxy guiding closing into H1 2027, would confirm.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Integer withdrew its FY2026 financial outlook on 2026-08-03 for the pendency of the KKR transaction; no company forecast exists while the merger is outstanding.",
    "Upside is contractually capped at $127 cash absent a superior proposal; the agreement carries a $154M company termination fee and a $307M parent reverse termination fee.",
    "Unvested RSU/PSU awards are 50% cashed out at closing and 50% remain subject to existing service vesting under the merger agreement (2026-08-03).",
    "NYSE-listed; the shares delist on closing, guided by the company to year-end 2026 with a merger-agreement outside date of 2027-05-02.",
    "Delaware Court of Chancery is the exclusive forum for certain merger-related actions under the deal documents filed 2026-08-03."
  ],
  "body_markdown": "## Current Thesis\nThe equity has traded as a deal instrument since 2026-08-03, when KKR's affiliate signed an all-cash agreement at **$127.00 per share**, enterprise value approximately **$5.7B**, board unanimous, no financing condition. The last completed daily close was **$125.20 (2026-08-21)** — **$1.80** beneath the stated consideration, about 1.4% of that close. Two weeks earlier the close was **$125.27 (2026-08-07)**. The gap has gone essentially nowhere: the market is pricing high completion odds and paying nothing for a topping bid. What an investor buys here is a countdown to a year-end 2026 closing guide against a **2027-05-02** outside date, with the equity's remaining headline upside contractually fixed.\n\nThe refresh point since the last note: the deal has entered its paperwork stage and the paperwork has not arrived. No PREM14A or DEFM14A merger proxy appears on Integer's SEC filing index as of 2026-08-22, and no 8-K has disclosed an HSR filing date or clearance.\n\n## Bull Case\n- **Terms are signed, not proposed (2026-08-03):** $127 cash, EV ~$5.7B, funded with equity from KKR-managed funds plus committed debt; lead arrangers named in the announcement were Citi, KKR Capital Markets, Barclays, UBS and Jefferies. No financing contingency.\n- **Fee asymmetry sits with the seller:** parent reverse termination fee **$307M** against a **$154M** company fee, per merger-agreement exhibits to the 2026-08-03 8-K. Against ~$5.7B of EV the company fee is not a prohibitive toll on a competing bid.\n- **The spread has held through two weeks of nothing.** From the 2026-08-07 close of $125.27 to the 2026-08-21 close of $125.20, price moved seven cents. Deal breaks are usually preceded by spread widening; none is visible in the endpoints.\n- **The Q2 print cleared consensus into signing:** sales **$464.110M** vs **$450.505M**, adjusted EPS **$1.60** vs **$1.42** (2026-08-03), with the 10-Q filed 2026-08-04. A quarter that beats weakens any later material-adverse-effect argument.\n- **Sponsor buyer, no device-manufacturing overlap.** The horizontal-overlap route to an antitrust problem is narrower than in a strategic deal. That is an inference from the buyer's identity; no regulatory position has been disclosed either way.\n- **Calendar slack:** roughly nine months of runway between signing and the 2027-05-02 outside date against a year-end guide.\n\n## Bear Case\n- **Upside is capped at $1.80.** At the 2026-08-21 close there is no fundamental path above $127 while this agreement stands, and no competing bidder has surfaced in the 19 days since signing.\n- **Sell-side is now fully collapsed onto the deal.** KeyBanc to Sector Weight (2026-08-03); Oppenheimer to Perform (2026-08-04); Truist to Hold, PT **$127**; Wells Fargo Equal-Weight, PT **$127** (both 2026-08-04); **Benchmark to Hold on 2026-08-14**. Five houses neutralized, two targets set exactly at the consideration. MarketBeat's aggregate showed a consensus Hold as of 2026-08-19.\n- **The un-deal anchors are far below.** Pre-leak marks: Citi Neutral **PT $96** (2026-07-08), Truist Buy **PT $110** (2026-07-16) — roughly 12% to 23% under the 2026-08-21 close.\n- **The standalone business is contracting.** Q2 2026 sales fell 2.6% YoY, organic sales -1.5%, and Integer **withdrew its FY2026 outlook** on 2026-08-03 and cancelled the 2026-08-06 call. No company forecast exists to underwrite a break price.\n- **Funding still has to clear a market.** No financing condition is a contractual protection; a ~$5.7B EV take-private — InsideArbitrage put the purchase at 16.36x EBITDA in its 2026-08 write-up — still meets the loan and high-yield bid between signing and funding.\n\n## Setup & Price Structure\nThe shares are up 40.2% over three months and sit 0.7% below the 52-week high of $126.07 — a step function from the 2026-07-31 WSJ leak (halted on an upside circuit breaker, up 11.05% intraday) and the 2026-08-03 signing, not a trend. The 52-week high itself sits $0.93 under the consideration; the tape has never paid full price.\n\n**The narrative is maturing.** The event is well known and still working. RSI(14) has decayed from 95.6 on 2026-08-07 to **60.7 on 2026-08-21** while price held within seven cents — the momentum reading normalized without any price given back, which is how a pinned deal stock behaves. Fresh attention has moderated: after seven news items in the 2026-07-31 to 2026-08-04 window, the only rating action in the following two weeks was Benchmark on 2026-08-14. The label flips to saturated if screen-driven coverage rebuilds while the spread stays inside 1.5%, and to dead on a disclosed second request or a break.\n\n**Crowding and positioning observables, stated as observables:** a Schedule 13G disclosing a 5.4% position by Nomura Group appears on the filing index dated 2026-08-14 (a passive-holder form; Nomura Group filings aggregate broker-dealer and derivative books, so it is not by itself evidence of directional arbitrage accumulation). Insider activity on file is July RSU grant-and-vest mechanics for Metcalf, Kirk and Harris (Form 4s 2026-07-01 and 2026-07-10) — no open-market sales reported. There is no earnings date to trade into: the Q2 call was cancelled and guidance withdrawn. Momentum and 52-week-high screens will keep surfacing a security whose headline reward is $1.80.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-02 (est.) — preliminary merger proxy (PREM14A).** Not on file as of 2026-08-22. Sets the special-meeting date and discloses the background of the merger, the financial analysis, and the full deal-protection package including any go-shop or matching rights.\n- **~2026-09-15 (est.) — expiry of the HSR initial 30-day waiting period.** The filing date has not been disclosed, so this estimate hangs off the 2026-08-03 signing. A clean expiry supports the year-end guide; a second request pushes toward 2027-05-02.\n- Nothing confirmed-dated falls inside the next 30 days. Both items above are estimates, and the absence of a scheduled event is itself the current state of the file.\n\n## What Would Change Our Mind\nThe calendar breaks before the price does. If 2026-09 closes with no merger proxy on file, the special meeting slides toward Q4 and the year-end 2026 closing guide stops being credible on arithmetic alone — that, or an 8-K disclosing an HSR second request, is what turns a 1.4% spread into a re-underwriting. On price, **a daily close below $118** — more than a 7% discount to the $127 consideration, well outside the band a committed no-financing-condition deal trades in — would mark the market repricing completion odds rather than merely drifting. In the other direction, a competing proposal disclosed in the proxy background, or a stated bid above $127, would reopen an upside the current terms foreclose. Passing 2026-12-31 without a close and without a restated target grades the timeline as slipped even if the spread holds.\n\n## Correlation Notes\n- The name has decoupled from the medtech contract-manufacturing complex. Whatever that group did between 2026-08-07 and 2026-08-21 did not reach this price; the endpoints moved seven cents. The live correlates are deal-specific.\n- The relevant macro sensitivity is credit rather than device end-markets: funding for a ~$5.7B EV take-private is exposed to leveraged-loan and high-yield conditions between signing and closing, even with no financing condition in the agreement.\n- A secondary correlate is the sponsor take-private pipeline and antitrust stance toward financial buyers; a visible second request elsewhere in large-cap LBO land would widen this spread by association rather than by anything Integer disclosed.\n- On a break, the equity re-correlates hard to its own fundamentals — Q2 sales -2.6% YoY, organic -1.5%, no FY2026 outlook — and toward the pre-leak $96–$110 analyst zone.",
  "first_seen": "2026-08-04",
  "last_analyzed": "2026-08-22T09:22:31+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}